Publications by authors named "Beatty P"

Insight into human physiology is key to maintaining diver safety in underwater operational environments. Numerous hazardous physiological phenomena can occur during the descent, the time at depth, the ascent, and the hours after a dive that can have enduring consequences. While safety measures and strict adherence to dive protocols make these events uncommon, diving disorders still occur, often with insufficient understanding of the factors that triggered the event.

View Article and Find Full Text PDF
Article Synopsis
  • - Flaviviruses are a group of viruses that cause serious diseases in humans, including dengue and Zika, and rely on a protein called NS1 for replication and disease severity.
  • - NS1 is secreted from infected cells and contributes to endothelial dysfunction, which affects blood vessel permeability and may facilitate the spread of the virus in the body.
  • - Research demonstrates that NS1 aids in the virus's ability to cross endothelial barriers and boosts the infectivity of specific target cells, indicating its crucial role in virus dissemination and its impact on disease progression.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between yellow fever virus (YFV) nonstructural protein 1 (NS1) and disease severity in yellow fever (YF) patients, highlighting how increased NS1 levels correlate with vascular dysfunction and severe clinical outcomes.
  • Researchers analyzed serum samples from patients with severe and non-severe YF cases, finding higher levels of NS1 and syndecan-1 (a vascular leak marker) in severe cases.
  • Results indicate that YFV NS1 contributes to endothelial dysfunction by inducing shedding of syndecan-1, suggesting these serum markers could be used for diagnosing and predicting disease severity in YF.
View Article and Find Full Text PDF

Genetic medicines show promise for treating various diseases, yet clinical success has been limited by tolerability, scalability, and immunogenicity issues of current delivery platforms. To overcome these, we developed a proteolipid vehicle (PLV) by combining features from viral and non-viral approaches. PLVs incorporate fusion-associated small transmembrane (FAST) proteins isolated from fusogenic orthoreoviruses into a well-tolerated lipid formulation, using scalable microfluidic mixing.

View Article and Find Full Text PDF

The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa.

View Article and Find Full Text PDF

Yellow fever virus (YFV) infections can cause severe disease manifestations, including hepatic injury, endothelial damage, coagulopathy, hemorrhage, systemic organ failure, and shock, and are associated with high mortality in humans. While nonstructural protein 1 (NS1) of the related dengue virus is implicated in contributing to vascular leak, little is known about the role of YFV NS1 in severe YF and mechanisms of vascular dysfunction in YFV infections. Here, using serum samples from qRT-PCR-confirmed YF patients with severe (n=39) or non-severe (n=18) disease in a well-defined hospital cohort in Brazil, plus samples from healthy uninfected controls (n=11), we investigated factors associated with disease severity.

View Article and Find Full Text PDF

Background: There is an unmet clinical need for minimally invasive diagnostic tests to improve the detection of grade group (GG) ≥3 prostate cancer relative to prostate antigen-specific risk calculators. We determined the accuracy of the blood-based extracellular vesicle (EV) biomarker assay (EV Fingerprint test) at the point of a prostate biopsy decision to predict GG ≥3 from GG ≤2 and avoid unnecessary biopsies.

Methods: This study analyzed 415 men referred to urology clinics and scheduled for a prostate biopsy, were recruited to the APCaRI 01 prospective cohort study.

View Article and Find Full Text PDF

Optimization of flow cytometry assays for extracellular vesicles (EVs) often fail to include appropriate reagent titrations - the most critically antibody titration is either not performed or is incomplete. Using nonoptimal antibody concentration is one of the main sources of error leading to a lack of reproducible data. Antibody titration for the analysis of antigens on the surface of EVs is challenging for a variety of technical reasons.

View Article and Find Full Text PDF

Background: Research has shown that patients may turn to social media seeking information regarding diagnosis and treatment. This study aimed to analyze and compare content related to hidradenitis suppurativa (HS) using the "hashtag" tool across three of the most popular social media platforms to determine the information that patients are exposed to online.

Methods: We identified hashtags across Instagram, TikTok, and Facebook for "#hidradenitissuppurativa.

View Article and Find Full Text PDF

The current research aims to investigate whether perspective taking influences social tuning, or the alignment of one's self-views, explicit attitudes, and/or implicit attitudes with those of an interaction partner. In six different experiments, participants believed they would interact with a partner to complete a task. Prior to this ostensible interaction, participants were given a perspective taking mindset prime, or not, and information about their ostensible interaction partners views.

View Article and Find Full Text PDF

Purpose: To assess whether MUC1 peptide vaccine produces an immune response and prevents subsequent colon adenoma formation.

Patients And Methods: Multicenter, double-blind, placebo-controlled randomized trial in individuals age 40 to 70 with diagnosis of an advanced adenoma ≤1 year from randomization. Vaccine was administered at 0, 2, and 10 weeks with a booster injection at week 53.

View Article and Find Full Text PDF